Neuromodulator / Merz Aesthetics
Bocouture
IncobotulinumtoxinA, formulation context and the ULTRA clinical programme.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
Clinical summary: UK BOCOUTURE. XEOMIN records are market-specific and do not extend this label.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
Botulinum toxin type A, 150 kDa, without complexing proteins; UK presentations contain 50 or 100 units.[2]
How it works#
Blocks cholinergic transmission by inhibiting acetylcholine release, temporarily reducing muscle contraction.[2]
Indications & treatment areas#
UK labeling covers moderate-to-severe glabellar, lateral periorbital and horizontal forehead lines in adults under 65 with important psychological impact.[2]
Application considerations#
Use product-specific preparation and anatomical assessment. Units are not interchangeable with other botulinum toxin preparations.[2]
Contraindications & precautions#
Relevant hypersensitivity, generalised muscle-activity disorders, and local infection or inflammation are contraindications. Review bleeding risk and neuromuscular dysfunction.[2]
Adverse effects & safety#
Ptosis, local reactions and distant muscle weakness are possible. Swallowing, speech or respiratory disorders require immediate medical care.[2]
Duration & follow-up#
The SmPC describes temporary effects and a minimum three-month treatment interval. ULTRA assessed day-30 efficacy and repeated-treatment extensions.[2][5]
Distinctions that matter#
Absence of complexing proteins describes formulation. The placebo-controlled ULTRA trials do not establish clinical superiority over other commercial toxins.[2][5]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
German 50- and 100-unit Fachinformation attached.[3]
UK SmPC attached; the local age and indication scope remains controlling.[2]
June 2026 US labeling includes glabellar, forehead and lateral canthal lines in adults; BOCOUTURE remains a distinct regional label.[1]
June 2024 public assessment attached as a historical decision record, not a current prescribing label.[4]
Studies worth a closer look.#
Studying the upper face as a whole.
Keep the randomized period separate from the extension when assessing certainty.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] XEOMIN US prescribing information ↗Merz / DailyMed · label · Document accessed · Document: Revised June 2026 · Checked 2026-09-06
- [2] BOCOUTURE Summary of Product Characteristics ↗Merz / emc · label · Document accessed · Checked 2026-09-06
- [3] BOCOUTURE German Fachinformation ↗Merz / Fachinfo · label · Document accessed · Checked 2026-09-06
- [4] XEOMIN Australian public assessment report ↗Therapeutic Goods Administration · regulator · Document accessed · Document: June 2024 · Checked 2026-09-06
- [5] IncobotulinumtoxinA — ULTRA I and ULTRA II ↗Aesthetic Surgery Journal · PMID 39475143 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. Bocouture. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/bocouture/